



Press communication

Lund, Sweden, May 16, 2023

*This is a translation of the Swedish press release published 2023-05-16*

## **Neola Medical granted patent in the U.S. which open opportunities for lung monitoring of more patient groups**

**Neola Medical AB (publ) announces today that the company has been granted a new patent in the U.S. for an invention. This invention can enable measurement on more patient groups than preterm born infants by positioning the light source inside the body when measuring gas in the lungs.**

“The U.S. is our most important market due to the large number of newborns, in particular the high rate of preterm born infants, and this patent is therefore of great strategic importance as it protects a significant part of the company’s technology. But what is perhaps even more essential is that the invention enables continuous lung monitoring in several patient groups, such as older children and perhaps also adults,” says Hanna Sjöström, CEO of Neola Medical.

The company already has a patent granted for the invention in China and has ongoing patent application for the invention in Europe.

### **For further information, contact:**

Hanna Sjöström, CEO Neola Medical, e-mail: [hanna.sjostrom@neolamedical.com](mailto:hanna.sjostrom@neolamedical.com)

---

*Neola Medical AB (publ) develops medical technology device for continuous monitoring of preterm born infants’ lungs. Immediate detection of complications provides the possibility of early treatment and improved health care. The patented technology is based on a spectroscopic method developed at Lund University in Sweden. The company was founded in 2016 as a wholly owned subsidiary of Gasporox AB (publ) under the name GPX Medical AB. The company is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more on [www.neolamedical.com](http://www.neolamedical.com). The company’s Certified Adviser is FNCA Sweden AB.*